Abstract
ABT-719 (A-86719.1) is the first compound of a new class of novel DNA gyrase inhibitors, the 2-pyridones, with potent antibacterial activity against gram-positive, gram-negative, and anaerobic organisms. ABT-719 was more active than ciprofloxacin, sparfloxacin, and clinafloxacin against gram-positive bacteria. ABT-719 was particularly active against Staphylococcus aureus (MIC at which 90% of the isolates were inhibited [MIC90] = 0.015 micrograms/ml) and Streptococcus pneumoniae (MIC90 = 0.03 micrograms/ml). ABT-719 was also the most active of the compounds tested against ciprofloxacin-resistant S. aureus isolates, with an MIC90 of 0.25 micrograms/ml, compared with 64 micrograms/ml for ciprofloxacin. Against gram-negative organisms, ABT-719 was as active as or slightly more active than ciprofloxacin and was the most active compound against ciprofloxacin-resistant Pseudomonas aeruginosa (MIC90 = 2.0 micrograms/ml). ABT-719 was also the most active compound against both gram-positive and gram-negative anaerobes, with MIC90s ranging from 0.12 to 0.25 micrograms/ml.
Full Text
The Full Text of this article is available as a PDF (218.3 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Azoulay-Dupuis E., Bedos J. P., Vallée E., Pocidalo J. J. Comparative activity of fluorinated quinolones in acute and subacute Streptococcus pneumoniae pneumonia models: efficacy of temafloxacin. J Antimicrob Chemother. 1991 Dec;28 (Suppl 100):45–53. doi: 10.1093/jac/28.suppl_c.45. [DOI] [PubMed] [Google Scholar]
- Barry A. L., Fuchs P. C. Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin. Eur J Clin Microbiol Infect Dis. 1991 Mar;10(3):168–171. doi: 10.1007/BF01964451. [DOI] [PubMed] [Google Scholar]
- Clement J. J., Tanaka S. K., Alder J., Vojtko C., Beyer J., Hensey D., Ramer N., McDaniel D., Chu D. T. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. Antimicrob Agents Chemother. 1994 May;38(5):1071–1078. doi: 10.1128/aac.38.5.1071. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cooper M. A., Andrews J. M., Ashby J. P., Matthews R. S., Wise R. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother. 1990 Nov;26(5):667–676. doi: 10.1093/jac/26.5.667. [DOI] [PubMed] [Google Scholar]
- Jones R. N., Kehrberg E. N., Erwin M. E., Anderson S. C. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group. Diagn Microbiol Infect Dis. 1994 Aug;19(4):203–215. doi: 10.1016/0732-8893(94)90033-7. [DOI] [PubMed] [Google Scholar]
- King A., Bethune L., Phillips I. The in-vitro activity of temafloxacin compared with other antimicrobial agents. J Antimicrob Chemother. 1991 Jun;27(6):769–779. doi: 10.1093/jac/27.6.769. [DOI] [PubMed] [Google Scholar]
- Mazzulli T., Simor A. E., Jaeger R., Fuller S., Low D. E. Comparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1990 Mar;34(3):467–469. doi: 10.1128/aac.34.3.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Raviglione M. C., Boyle J. F., Mariuz P., Pablos-Mendez A., Cortes H., Merlo A. Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital. Antimicrob Agents Chemother. 1990 Nov;34(11):2050–2054. doi: 10.1128/aac.34.11.2050. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Thys J. P., Jacobs F., Motte S. Quinolones in the treatment of lower respiratory tract infections. Rev Infect Dis. 1989 Jul-Aug;11 (Suppl 5):S1212–S1219. doi: 10.1093/clinids/11.supplement_5.s1212. [DOI] [PubMed] [Google Scholar]
- Waites K., Rand K., Jenkins S., Yangco B., Brookings E., Gaskins D., Lewis J., Halkias K. Multicenter in vitro comparative study of fluoroquinolones after four years of widespread clinical use. Diagn Microbiol Infect Dis. 1994 Mar;18(3):181–189. doi: 10.1016/0732-8893(94)90089-2. [DOI] [PubMed] [Google Scholar]